233 related articles for article (PubMed ID: 23538750)
1. Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity.
Zhao X; Lwin T; Zhang X; Huang A; Wang J; Marquez VE; Chen-Kiang S; Dalton WS; Sotomayor E; Tao J
Leukemia; 2013 Dec; 27(12):2341-50. PubMed ID: 23538750
[TBL] [Abstract][Full Text] [Related]
2. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.
Zhang X; Zhao X; Fiskus W; Lin J; Lwin T; Rao R; Zhang Y; Chan JC; Fu K; Marquez VE; Chen-Kiang S; Moscinski LC; Seto E; Dalton WS; Wright KL; Sotomayor E; Bhalla K; Tao J
Cancer Cell; 2012 Oct; 22(4):506-523. PubMed ID: 23079660
[TBL] [Abstract][Full Text] [Related]
3. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms.
Koh CM; Iwata T; Zheng Q; Bethel C; Yegnasubramanian S; De Marzo AM
Oncotarget; 2011 Sep; 2(9):669-83. PubMed ID: 21941025
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas.
Tian X; Pelton A; Shahsafaei A; Dorfman DM
Mod Pathol; 2016 Sep; 29(9):1050-7. PubMed ID: 27282353
[TBL] [Abstract][Full Text] [Related]
5. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a.
Sander S; Bullinger L; Klapproth K; Fiedler K; Kestler HA; Barth TF; Möller P; Stilgenbauer S; Pollack JR; Wirth T
Blood; 2008 Nov; 112(10):4202-12. PubMed ID: 18713946
[TBL] [Abstract][Full Text] [Related]
6. DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations.
Akpa CA; Kleo K; Lenze D; Oker E; Dimitrova L; Hummel M
PLoS One; 2019; 14(8):e0220681. PubMed ID: 31419226
[TBL] [Abstract][Full Text] [Related]
7. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2.
Lu J; He ML; Wang L; Chen Y; Liu X; Dong Q; Chen YC; Peng Y; Yao KT; Kung HF; Li XP
Cancer Res; 2011 Jan; 71(1):225-33. PubMed ID: 21199804
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of MYC and EZH2 cooperates to epigenetically silence MST1 expression.
Kuser-Abali G; Alptekin A; Cinar B
Epigenetics; 2014 Apr; 9(4):634-43. PubMed ID: 24499724
[TBL] [Abstract][Full Text] [Related]
9. Targeting miR-21 with NL101 blocks c-Myc/Mxd1 loop and inhibits the growth of B cell lymphoma.
Li S; He X; Gan Y; Zhang J; Gao F; Lin L; Qiu X; Yu T; Zhang X; Chen P; Tong J; Qian W; Xu Y
Theranostics; 2021; 11(7):3439-3451. PubMed ID: 33537096
[No Abstract] [Full Text] [Related]
10. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X
Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway.
Zhang P; Yang X; Ma X; Ingram DR; Lazar AJ; Torres KE; Pollock RE
Mol Cancer; 2015 Mar; 14():55. PubMed ID: 25890085
[TBL] [Abstract][Full Text] [Related]
12. A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas.
Lwin T; Zhao X; Cheng F; Zhang X; Huang A; Shah B; Zhang Y; Moscinski LC; Choi YS; Kozikowski AP; Bradner JE; Dalton WS; Sotomayor E; Tao J
J Clin Invest; 2013 Nov; 123(11):4612-26. PubMed ID: 24216476
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2.
Ma DN; Chai ZT; Zhu XD; Zhang N; Zhan DH; Ye BG; Wang CH; Qin CD; Zhao YM; Zhu WP; Cao MQ; Gao DM; Sun HC; Tang ZY
J Hematol Oncol; 2016 Jan; 9():1. PubMed ID: 26733151
[TBL] [Abstract][Full Text] [Related]
14. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression.
Bao B; Ali S; Banerjee S; Wang Z; Logna F; Azmi AS; Kong D; Ahmad A; Li Y; Padhye S; Sarkar FH
Cancer Res; 2012 Jan; 72(1):335-45. PubMed ID: 22108826
[TBL] [Abstract][Full Text] [Related]
15. EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity.
Yan J; Ng SB; Tay JL; Lin B; Koh TL; Tan J; Selvarajan V; Liu SC; Bi C; Wang S; Choo SN; Shimizu N; Huang G; Yu Q; Chng WJ
Blood; 2013 May; 121(22):4512-20. PubMed ID: 23529930
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-26a is a key regulon that inhibits progression and metastasis of c-Myc/EZH2 double high advanced hepatocellular carcinoma.
Zhang X; Zhang X; Wang T; Wang L; Tan Z; Wei W; Yan B; Zhao J; Wu K; Yang A; Zhang R; Jia L
Cancer Lett; 2018 Jul; 426():98-108. PubMed ID: 29653269
[TBL] [Abstract][Full Text] [Related]
17. Polycomb repressive complex 2 (PRC2) suppresses Eμ-myc lymphoma.
Lee SC; Phipson B; Hyland CD; Leong HS; Allan RS; Lun A; Hilton DJ; Nutt SL; Blewitt ME; Smyth GK; Alexander WS; Majewski IJ
Blood; 2013 Oct; 122(15):2654-63. PubMed ID: 23982173
[TBL] [Abstract][Full Text] [Related]
18. Acquired resistance to DZNep-mediated apoptosis is associated with copy number gains of AHCY in a B-cell lymphoma model.
Akpa CA; Kleo K; Oker E; Tomaszewski N; Messerschmidt C; López C; Wagener R; Oehl-Huber K; Dettmer K; Schoeler A; Lenze D; Oefner PJ; Beule D; Siebert R; Capper D; Dimitrova L; Hummel M
BMC Cancer; 2020 May; 20(1):427. PubMed ID: 32408898
[TBL] [Abstract][Full Text] [Related]
19. Mutant p53 induces EZH2 expression and promotes epithelial-mesenchymal transition by disrupting p68-Drosha complex assembly and attenuating miR-26a processing.
Jiang FZ; He YY; Wang HH; Zhang HL; Zhang J; Yan XF; Wang XJ; Che Q; Ke JQ; Chen Z; Tong H; Zhang YL; Wang FY; Li YR; Wan XP
Oncotarget; 2015 Dec; 6(42):44660-74. PubMed ID: 26587974
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of microRNA-26a is associated with metastatic potential and the poor prognosis of osteosarcoma patients.
Song QC; Shi ZB; Zhang YT; Ji L; Wang KZ; Duan DP; Dang XQ
Oncol Rep; 2014 Mar; 31(3):1263-70. PubMed ID: 24452597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
